Poolbeg expects first data for CRS drug in the summer

▤ Summary

Poolbeg Pharma is preparing to start a clinical trial for POLB-001, a drug designed to prevent cytokine release syndrome in cancer immunotherapy patients. The company has activated its first investigation site and expects to collect initial data in the summer. The TOPICAL trial will run across six NHS hospitals in 30 multiple myeloma patients receiving Johnson & Johnson’s Tecvayli. Poolbeg believes the drug could broaden access to immunotherapies and address a large global market if the study results are positive.

▦ Linked Companies